Fig. 1

Bioluminescence analysis of Nfe2l2 activation in ARE-luc2 reporter mice treated with CBE. A Schematic representation of the experiments, reporting the timing of the pharmacological treatments and the in vivo/ex vivo imaging sessions. B Representative pictures of the in vivo bioluminescence detected in the selected regions of interest (ROI, red square) in the head area: the bioluminescence signal is shown as radiance photons (p/s/cm²/sr) and represented as pseudocolors, according to the reported scale bar. C Bioluminescence imaging (BLI) quantifications of the photon emission from the ROI shown in B; the measures of bioluminescence signal are reported in the graph as fold change (FC) of the radiance photons measured at the end of the pharmacological treatment (day 3) versus the radiance photons measured before the treatment with tBHQ (day 2). D Representative ex vivo bioluminescence imaging of the brain dissected in five sections (slices I–V) and the schematic representation of the different brain areas in each slide. CB, cerebellum; Ctx, cerebral cortex; HT, hypothalamus; OB, olfactory bulb; SN, substantia nigra; TH, thalamus. Bioluminescence signals were acquired for each brain section at the end of the pharmacological treatments and are shown as radiance photons (p/s/cm²/sr) and represented as pseudocolors, according to the reported scale bar. Quantification of the BLI signals from whole brain and brain slices are reported in E and F–L, respectively: the measures of bioluminescence signal are reported in the graph as fold change (FC) of the radiance photons versus vehicle and presented as mean ± SD of n=4 independent samples measured in duplicate. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001